This website isn’t supported by Internet Explorer. We recommend that you use a different browser (e.g. Edge, Chrome, Firefox, Safari, or similar) for the best experience of our content.
/ ... / /
/ ... / /

For healthcare professionals only

You are viewing the Novo Nordisk Virtual platform, provided to non-US health care professionals from around the world. By accessing this site and materials you accept this legal notice and expressly confirm your status as a healthcare professional.

 

This site is not country-specific and therefore may contain information which is not applicable to your country. Therefore, before prescribing any product, always refer to local materials such as the prescribing information and/or the Summary of Product Characteristics.

 

This site is not intended to provide medical advice and/or treatment guidance. Novo Nordisk accepts no liability for the accuracy, completeness or use of the information, and disclaims any liability to update the information contained on this site.

I hereby declare I am a non-US health care professional and that I have read and agreed to the terms mentioned above.

abbott image

NovoPen® 6 and NovoPen Echo® Plus users can now connect their devices to the FreeStyle LibreLink app.*

This technology replaces paper-based insulin dose logs, which can be time-consuming to create and prone to errors, missing data, or incomplete information.

NovoPen® 6 and NovoPen Echo® Plus record insulin dosing information with each injection. Users can automatically and easily transfer their dose log to FreeStyle LibreLink by scanning their smart NovoPen® with their smartphone.

The insulin doses are displayed along with the glucose data in the FreeStyle LibreLink app and LibreView.**

This can help people living with diabetes and their healthcare teams to see how different factors, like dose timing and the amount of insulin taken, impact their individual glucose patterns.

Reset all filters

{{numberOfResults}} {{resultString}}

The sensor housing, FreeStyle Libre and related brand marks are marks of Abbott and used with permission. Images are for illustrative purposes only. Not real patient data. Therefore, the mobile app experience may not look exactly as depicted here. FreeStyle LibreLink works with FreeStyle Libre or FreeStyle Libre 2 sensors and is only compatible with NovoPen® 6 and NovoPen Echo® Plus.

 

* The FreeStyle LibreLink app is only compatible with certain mobile devices and operating systems. Please check the website for more information about device compatibility before using the app. Use of FreeStyle LibreLink app may require registration with LibreView. Product availability may vary by country. Not all features are available in all markets. If you require product information for a specific country, please refer to your local Abbott website.

 

** The LibreView data management software is intended for use by both patients and healthcare professionals to assist people with diabetes and their healthcare professionals in the review, analysis, and evaluation of historical glucose meter data to support effective diabetes management. The LibreView software is not intended to provide treatment decisions or to be used as a substitute for professional healthcare advice. 

Smart pens. Smarter Care

The smart insulin pens NovoPen® 6 & NovoPen Echo® Plus are designed to improve insulin dose recording. This may help HCPs to have informed discussions with diabetes patients based on individual injection data.1-3
dose check

 

Designed to simplify initiation and titration of basal insulin. Discover how Dose Check can help you and your patients with daily insulin dose guidance.

Digital Health Partnerships

Get to know the ecosystem of Novo Nordisk’s digital health partners.

1.

Data on File. NovoPen® 6 & NovoPen Echo® Plus Design Specification/Verification Report.

2.

Adolfsson P, Hartvig NV, Kaas A, Møller JB, Hellman J. Increased time in range and fewer missed bolus injections after introduction of a smart connected insulin pen. Diabetes Technology & Therapeutics. 2020; 22(10): 709-718.

3.

Klonoff DC, Kerr D. Smart pens will improve insulin therapy. J Diabetes Sci Technol. 2018; 12(3): 551-553.

 

NovoPen® 6 and NovoPen Echo® Plus are CE-marked medical devices. Notified body 0123. 

NovoPen® 6 and NovoPen Echo® Plus are certified against the EU Medical Device Directive (MDD) 93/42/EEC.

NovoPen® 6 and NovoPen Echo® Plus are available in a number of countries with additional launches planned in the near future. Timeframes will vary according to device, insulin brand and unique market regulations.

 

Dose Check is CE marked. Notified body 1282. Dose Check is certified against the EU Medical Device Directive (MDD), 93/42/EEC.
Manufacturer: Amalgam Rx, Inc. 1007 N. Orange St, Ste. 400, Wilmington, DE 19801, USA Authorized Representative: Medical Device Safety Service GmbH, Schiffgraben 41, 30175 Hannover, Germany.
Dose Check is available in a number of countries and additional launches are planned in the near future. Timeframes will vary according to device, insulin brand and unique market regulations. Dose guidance apps and the information contained in these materials are not intended as a substitute for professional medical advice.

 

The information contained on this site is intended for healthcare professionals only outside of the United States of America. This site is not intended to provide medical advice and/or treatment guidance. Only a physician can determine whether a specific product is suitable for a particular patient. This site is not country-specific and therefore may contain information which is not applicable to your country. Novo Nordisk accepts no liability for the accuracy, completeness, or use of this information, and disclaims any liability to update the information contained on this site. By accessing this site and materials you accept this legal notice and expressly confirm your status as a healthcare professional. Any images shown are models and not real patients.

 

HQ24NP600020, June 2024